The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Indications for the device
Availability for follow-up at an approved Field Following center, at the protocol defined intervals
Willing and capable of undergoing a device implant and participating in all testing associated with this clinical investigation
Prescribed to stable optimal pharmacologic therapy for HF
Age 18 or above, or of legal age to give informed consent specific to national law
Able to provide documented evidence of one or more episodes of AF/AT within 12 months of implantation NOTE: Guidant recommends anticoagulation therapy per physician discretion.
Right bundle branch block morphology
Life expectancy of less than six months due to other medical conditions
Expectation of a heart transplant during the period of the study
Patients with or who are likely to receive a mechanical tricuspid valve during the course of the study
Have a preexisting unipolar pacemaker that will not be explanted/abandoned
Have an atrial tachyarrhythmia that is permanent (i.e., does not terminate spontaneously and cannot be terminated with medical intervention) within 180 days prior to enrollment
Have a known hypersensitivity to dexamethasone acetate
Enrolled in any other study, including drug investigation
Women that are pregnant or planning to become pregnant
A Cerebral Vascular Event/ Transient Ischemic Attack within 12 months of implantation
During the four weeks prior to implantation, a patient experiences an episode of AF >= 48 hours in duration and was not anticoagulated for at an adequate therapeutic level (INR >= 2.0) for the 4 weeks prior to enrollment